hotspot -WSS

hotspot

author：comprehensive 2025-10-01 16:38:29 - browse：31793

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Plastic surgeons increase patient psychiatric screenings

WSS

Winning ticket for $1 billion Powerball jackpot sold in California

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Methadone treatment changes are coming. Do they go far enough?

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Stanford president's case begs question: Who takes blame?

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

leisure time

hotspot

Gilead needs Arcellx more than ever

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Judge rejects Trump's request to move Stormy Daniels hush

Apple is now the first public company to be valued at $3 trillion

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Duchenne breakthrough therapy leaves behind pioneering families

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Activists slam private health insurers over coverage restrictions

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: Bluebird, CVS, Contineum

Wikipedia

Ending racial health disparities hinges on penalties, political will

Stop the failed accountable care organization experiment

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Orchard's therapy for neuron disease in children wins FDA approval

Driven by the pandemic, applicants flood public health schools

Judge rejects Trump's request to move Stormy Daniels hush

explore

focus

hotspot

leisure time